IRX about to embark on phase 2 trials soon for a drug that if successful will be able to replace or offer a safer alternative to fetanyl. Company is run by experts (Dr Sud) in the field using a low cash burn model to maximize shareholder value and outcomes. It is not run by ex rugby league players with no medical science experience looking to stick their greedy snout as deep as they can into shareholders pockets (trough). Webinar next week. Better options out there….
IHL Price at posting:
4.1¢ Sentiment: None Disclosure: Not Held
